Board of Directors
Timothy C. Moynahan is the CEO and owner of Moynahan Partners. He founded the Moynahan Law Firm, Waterbury, Connecticut, and is a sought after and successful trial lawyer, earning the Super Lawyer of New England and Connecticut awards from 2009 to 2012 and Best Criminal Defense Attorney accolade in 2013. Mr. Moynahan seeks to improve his community through social, health, and education works. He founded and chairs the Global Virus Network (GVN). He is also a member of the Advisory Board and Executive Committee of the Institute of Human Virology, Vice President/Partner of Paula Moynahan M.D. Skin Care, member of the Post University MBA Advisory Council, and Attorney Emeritus for the Let’s Think Kids Foundation. He was a member of the Dean’s Council, School of Law, Quinnipiac University, and was a discussant on global business practice in Cyprus for the Southern Connecticut State University. Prior to this, Mr. Moynahan founded and chaired The Palace Theatre to preserve the cultural icon. Mr. Moynahan is President of the Ireland Chamber of Commerce in Connecticut. He has served as an advisor for the NBA Retired Players Association as Board member for the Leukemia Lymphoma Society, and chaired events for the Ataxia Telangiectasia Foundation, and the Order of the Sons of Italy. Post University inducted Mr. Moynahan into its Hall of Fame, named The Timothy C. Moynahan Law Library in his honor and awarded him a Doctor of Letters degree.
Lawrence Blatt, PhD. Global Head of Infectious Diseases, the Janssen Pharmaceutical Companies of Johnson& Johnson and President and CEO, Alios Biopharma
Lawrence Blatt, Ph.D. is responsible for co-leading the Infectious Diseases & Vaccines (IDV) Therapeutic Area at Janssen Research & Development. Prior to joining the Johnson & Johnson Family of Companies, Lawrence founded and was President and Chief Executive Officer of Alios BioPharma, Inc., the clinical stage biopharmaceutical company focused on developing therapies for viral diseases that was acquired by Johnson & Johnson in 2014. He was named as key inventor on several Alios patents and won the 2012 Ernst & Young Entrepreneur of the Year Award for Life Sciences. Lawrence spent 30 years in pharmaceutical R&D with a specific focus on the biology of the immune system, antiviral therapies and relevant therapeutic interventions. Before forming Alios, he was Chief Scientific Officer of InterMune, Inc. where he led the discovery and development of an HCV protease inhibitor partnered with Roche. From 1998 to 2002, Lawrence was Vice President of Research at SIRNA. From 1996 to 1998, he served as Vice President, Product Development at National Genetics Institute where he pioneered the use of molecular diagnostics to drive therapeutic treatment decisions for viral infections. He began his career at Amgen where he was ultimately Head of Interferon Research and also Development Team Leader for a consensus interferon product leading to approval by the United States Food and Drug Administration (FDA). Lawrence earned his B.S. in Microbiology from Indiana University, a Master’s in Business Administration at the California State University, Northridge, and a Doctorate in Public Health Administration at the University of La Verne, California.
Andrew Cheng, MD, PhD, Gilead Sciences, Inc.
Andrew Cheng has been Senior Vice President of Development Operations at Gilead Sciences Inc., since January 2009. Dr. Cheng is responsible for Gilead’s biometrics, clinical operations, drug safety and public health, project and portfolio management, and regulatory affairs activities. He joined Gilead in 1999 and served as Vice President, Clinical Research, overseeing clinical development activities for Gilead’s development-stage programs in HIV/AIDS. Prior to joining Gilead, he trained in internal medicine at the University of California, Los Angeles. Dr. Cheng received his Medical Degree and PhD in Cellular and Molecular Biology from Columbia University and undergraduate degree from the Johns Hopkins University.
Robert C. Gallo, MD, Director, Institute of Human Virology at the University of Maryland School of Medicine. The Homer & Martha Gudelsky Distinguished Professor in Medicine.
Co-founder & Scientific Director, Global Virus Network.
The Institute of Human Virology (IHV) was co-founded and is directed by Robert C. Gallo, MD, the eminent scientist who became world famous in 1984 when he co-discovered HIV as the cause of AIDS. Little was known then of the mysterious disease that was fast becoming the deadliest in medical history. Since, Dr. Gallo has spent much of his career trying to put an end to this raging epidemic and other viral, chronic illnesses.
Though best known for his co-discovery of HIV, Gallo and his team pioneered the development of the HIV blood test, which enabled health care workers for the first time to screen for the AIDS virus – leading to a more rapid diagnosis while simultaneously protecting patients receiving blood transfusions. His research also helped physicians develop HIV therapies to prolong the lives of those infected with the virus. In 1996, his discovery that a natural compound known as chemokines can block HIV and halt the progression of AIDS was hailed by Science magazine as one of that year’s most important scientific breakthroughs. This also helped others identify CCR5 as the HIV co-receptor since these chemokines were known to bind to CCR5.
Prior to the AIDS epidemic, Gallo was the first to identify a human retrovirus and the only known human leukemia virus – HTLV – one of few known viruses shown to cause a human cancer. In 1976, he and his colleagues discovered Interleukin-2, a growth regulating substance now used as therapy in some cancers and sometimes AIDS. And in 1986, he and his group discovered the first new human herpes virus in more than 25 years (HHV-6), which was later shown to cause an infantile disease known as Roseola and currently is hypothesized as a strong suspect in the origin of multiple sclerosis.
Today, Dr. Gallo’s work continues at the IHV, a first-of-its-kind virology center that combines the disciplines of research, patient care and prevention programs in a concerted effort to speed the pace of medical breakthroughs. In addition to Dr. Gallo, IHV was also co-founded by William Blattner, MD, retired since 2016 and formerly associate director of the IHV and director of IHV’s Division of Epidemiology and Prevention and Robert Redfield, MD, associate director of the IHV and director of IHV’s Division of Clinical Care and Research. IHV is also comprised of a Basic Science Division, Vaccine Research Division, Immunotherapy Division, and four Scientific Core Facilities. The Institute is a part of the University of Maryland School of Medicine and affiliated with the University of Maryland Medical Center. IHV’s patient base includes approximately 6,000 in Baltimore and Washington, D.C., and more than 1.3 million in African and Caribbean nations. In particular, IHV is internationally renowned for its basic science and vaccine research, which includes a preventive HIV vaccine candidate in human clinical trials and funded largely by the Bill & Melinda Gates Foundation.
Additionally, in 2011 Dr. Gallo co-founded the Global Virus Network (GVN) to position the world to rapidly respond to new or re-emerging viruses that threaten mankind, to bring together and achieve collaboration amongst the world’s leading virologists, and to support training of the next generation of medical virologists.
Prior to becoming director of the Institute in 1996, Dr. Gallo spent 30 years at the National Institutes of Health’s National Cancer Institute, where he was head of its Laboratory of Tumor Cell Biology. A Connecticut native, his interest in science and medicine was first stirred by the loss of his 6-year-old sister to leukemia when he was just 12 years old. The physicians who cared for her made a lasting impression and Gallo would later make scientific research – and the opportunity to help put an end to deadly diseases – his life’s work.
Lifetime achievements in Dr. Gallo’s legendary career include discoveries that have led to both diagnostic and therapeutic advances in cancer, AIDS and other viral disorders while his vision remains unprecedented in the field of virology.
Dr. Gallo’s research has brought him international recognition as well as election into the National Academy of Sciences and the Institute of Medicine. He has been awarded honors for his contribution to science from countries around the world and holds 35 honorary doctorates. Dr. Gallo was the most referenced scientist in the world in the 1980s and 1990s, during which he had the unique distinction of twice winning America’s most prestigious scientific award – the Albert Lasker Award in Medicine – in 1982 and again in 1986. Dr. Gallo is the author of more than 1,200 scientific publications and the book “Virus Hunting – AIDS, Cancer & the Human Retrovirus: A Story of Scientific Discovery.”
Mathew L. Evins, Chairman and CEO of Evins, Ltd.
Mr. Evins has served as Chairman and CEO of Evins, Ltd., a leading branding, marketing, communications and public relations firm since 1987. Mr. Evins previously served as CEO of Pain Therapeutics Corporation, which was engaged in developing innovative methods for the diagnosis, treatment, and abatement of chronic pain, and copublished “The Talisman Report,” the world’s leading investment advisory newsletter for the three years of its publication. For more than ten years, Mr. Evins served on the staff of Cornell Medical Center, initially as a Surgical Research Associate in the Cardiovascular Research Laboratory and, subsequently, as Associate Director of The Rogosin Organ Retrieval & Preservation Laboratory. Mr. Evins is a member of the Board of Directors of Hommage Inc., as well as a founding member, Treasurer and a member of the Executive Committee of the Board of directors of the Global Virus Network.
William “Billy” Hall, GVN-Co-Founder, is the Director of the Centre for Research in Infectious Diseases (CRID) and Professor in the School of Medicine and Medical Science at University College Dublin. Professor Hall’s research interests are primarily on blood-borne viruses which include the human retroviruses, the human T lymphotropic viruses (HTLVs) and human immunodeficiency viruses (HIVs). Professor HaII has also recently established high profile collaboration with the National Institute of Hygiene and Epidemiology (NIHE) in Hanoi, Vietnam to carry out epidemiological studies on HIV and Hepatitis Band C virus infections in that country. Professor Hall is presently Chairman of the Technical Advisory Group of Irish Government Department of Foreign Affairs official aid program, Irish Aid. This group advises Irish Aid on the use of resources to combat HIV/AIDS and other communicable diseases. He has been a Director of the Atlantic Philanthropies since 2008.
Peter Palese, PhD. Horace W. Goldsmith Professor and Chair Department of Microbiology. Professor, Department of Medicine Icahn School of Medicine at Mount Sinai.
Peter Palese is Professor of Microbiology and Chair of the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York. His research is in the area of RNA-containing viruses with a special emphasis on influenza viruses. Specifically, he established the first genetic maps for influenza A, B, and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals). He developed the field of reverse genetics for negative strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses. An improvement of the technique has been effectively used by him and his colleagues to reconstruct and study the pathogenicity of the highly virulent, but extinct, 1918 pandemic influenza virus. His recent work in collaboration with García-Sastre has revealed that most negative strand RNA viruses possess proteins with interferon antagonist activity, enabling them to counteract the antiviral response of the infected host. At present, Palese’s group works with Adolfo García-Sastre and Florian Krammer on the development of a universal influenza virus vaccine. He was a recipient of the Robert Koch Prize in 2006, a recipient of the European Virology Award (EVA) in 2010, a recipient of the 2012 Sanofi-Institut Pasteur Award, and the awardee of the 2015 Beijerink Virology Prize of the Royal Netherlands Academy of Arts and Sciences. He is a Member of the National Academy of Sciences (2000), a Member of the National Academy of Medicine (2012) and a Fellow of the American Academy of Arts and Sciences (2014).
Pierluigi Petrone, CEO of Petrone Group.
Mr. Petrone is the export manager, shareholder and CEO of Petrone Group with head office in Naples, Italy. A holding company of approximately 30 firms, operating in the pharmaceutical, parapharmaceutical and health sectors. Petrone Group activities goes from pharmaceuticals distribution and warehousing , pharmaceuticals trading, training course to healthy sectors, real estate management, health consultancy and rehabilitation. Since 2007, Mr. Petrone is the Chairman of STM Group Logistica Integrata, Italian company among the top 5 active in the supply chain of drugs in particular but also of any other kind of goods. Since 2008, Mr. Petrone is a Business Relation Officer of Pierrel S.p.A., listed on the Italian Stock Exchange since May 2006, is today a full service global provider for life science, biopharma and pharmaceutical industries.
Raymond F. Schinazi PhD, Hon DSc, Frances Winship Walters Professor of Pediatrics and Director, Laboratory of Biochemical Pharmacology, Emory University School of Medicine.
Dr. Raymond F. Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University. He serves as Senior Research Career Scientist at the Atlanta Department of Veterans Affairs and Director of the Scientific Working Group on Viral Eradication for the NIH-sponsored Emory University Center for AIDS Research (CFAR). Dr. has authored over 500 peer-reviewed papers and 7 books and holds 92 issued U.S. patents and over 120 non-U.S. national stage patents and patent applications, which have resulted in 15 New Drug Applications (NDA). A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine/Emtriva), LdT (telbivudine), and most recently sofosbuvir (Sovaldi), which are now approved by the FDA. He is also the founder of five biotechnology companies including Pharmasset, Inc. More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented, and it is estimated that his work has saved more than 4 million lives worldwide. His contributions related to HCV are expected to have a profound positive impact on the approximately 170 million people worldwide suffering from chronic infection.
Guangqi Tian, President and Founder of Sino Invest Limited.
Mr. Guangqi Tian is the President and Founder of Sino Invest Limited. He founded multiple companies in Harbin, Tianjin, and Beijing since 2005 and is owner or partial owner of businesses in Beijing, Tianjing, Hong Kong, US, Panama, and Dubai. He is engaged in international trade, investment and other businesses and has advised several Chinese state-owned companies on projects and ventures overseas and played instrumental roles in helping them win more than ten construction and investment contracts in Africa, Latin America, and Asia. Mr. Tian has invested in and managed commercial real estate projects in Tianjing. He has established and maintained good working relationships with different social entities in China, including, but not limited to, central and local governments and various business communities.
Guy Vernet, PhD, Senior Staff Scientist Advanced Bioscience Laboratories Inc. (ABL) Advanced Bioscience Laboratories Inc. (ABL), Fondation Merieux USA. (Board Member to be nominated)
He is a doctor in biochemistry from Claude Bernard University in Lyon, Guy Vernet occupied during 18 years (1990–2007) several positions within the R&D Department of bioMérieux, Dr. Vernet was Fondation Mérieux’s Scientific Director. He has led many research projects with the goal to improve the diagnosis of major human pathologies, in particular HIV infection, hepatitises and tuberculosis. Previously, he occupied during 3 years (1986–1989) a position of Assistant Professor at Biozentrum, University of Basel (Swizterland), in the team of Professor Edward Kellenberger, one of the pioneers of Molecular Biology. In 1985, he led a research project in immunology in the Research Centre on Animal Trypanosomiases of Bobo-Dioulasso in Burkina Faso, as part of the French co-operation. In the scope of his doctorate work, undertaken within INSERM from 1981 to 1984, he carried out research on the role of genes of some retroviruses in the process of canceration.
Danny Wong, Founder/Chairman of Medisun.
Mr. Wong is a graduate of China Central University of Finance, and he has over 20 years of experience in investment. He has successfully helped to launch dozens of high-tech companies in HK. In 1999 he founded the first venture capital company in China. Mr. Wong currently serves as Chairman of Beijing Financial Group Limited which covers a full financial industry chain, including brokerage, asset management and wealth management companies established in Hong Kong. In the past two decades he has made substantial investments in the healthcare industry.